Clinical trial

Ghrelin and Beta Cell Function in Diabetes

NCT02440061

StatusWITHDRAWN

Study typeINTERVENTIONAL

Start date2018-05-01

PhasePHASE1

Study timeline

Study start (estimated)2018-05-01Date precision: month

Registry last updated2018-04-02

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Type 2 Diabetes Mellitusunresolved

Interventions

Synthetic human AGDRUG

ArginineDRUG · verified · RxNorm: arginine

0.9% saline solutionDRUG

Sponsors & collaborators

Jenny Tong, MD, MPHlead sponsor

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)collaborator

Mapped research locations

DurhamNorth Carolina, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02440061 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.